title: Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells.
abstract: Taxanes are powerful chemotherapy agents that target the microtubule cytoskeleton, leading to mitotic arrest and cell death; however, their clinical efficacy has been hampered due to the development of drug resistance. Therefore, other proteins involved in spindle assembly are being examined as potential targets for anticancer therapy. The mitotic kinesin, Eg5 is critical for proper spindle assembly; as such, inhibition of Eg5 leads to mitotic arrest making it a potential anticancer target. We wanted to validate Eg5 as a therapeutic target and determine if Eg5 inhibitors retain activity in Taxol-resistant cells. Using affinity chromatography we first show that the compound HR22C16 is an Eg5 inhibitor and does not interact with other microtubule motor proteins tested. Furthermore, HR22C16 along with its analogs, inhibit cell survival in both Taxol-sensitive and -resistant ovarian cancer cells with at least 15-fold greater efficacy than monastrol, the first generation Eg5 inhibitor. Further analysis with HR22C16-A1, the most potent HR22C16 analog, showed that it retains efficacy in PgP-overexpressing cells, suggesting that it is not a PgP substrate. We further show that HR22C16-A1 induces cell death following mitotic arrest via the intrinsic apoptotic pathway. Interestingly, the combination of HR22C16-A1 with Taxol results in an antagonistic antiproliferative and antimitotic effect, possibly due to the abrogation of Taxol-induced mitotic spindles by HR22C16-A1. Taken together, our results show that Eg5 inhibitors have promising anticancer activity and can be potentially used to overcome Taxol resistance in the clinical setting.
authors.affiliation: Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia 30322, USA.
authors.forename: Adam I
authors.initials: AI
authors.lastname: Marcus
authors.forename: Ulf
authors.initials: U
authors.lastname: Peters
authors.forename: Shala L
authors.initials: SL
authors.lastname: Thomas
authors.forename: Sarah
authors.initials: S
authors.lastname: Garrett
authors.forename: Amelia
authors.initials: A
authors.lastname: Zelnak
authors.forename: Tarun M
authors.initials: TM
authors.lastname: Kapoor
authors.forename: Paraskevi
authors.initials: P
authors.lastname: Giannakakou
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007211:Indoles / Q000494:pharmacology*; D016547:Kinesins / Q000037:antagonists & inhibitors*; D008870:Microtubules / Q000187:drug effects; D008938:Mitosis / Q000187:drug effects*; D017239:Paclitaxel / Q000494:pharmacology*; D010636:Phenols / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; C483533:HR22C16; D007211:Indoles; C470243:KIF11 protein, human; D010636:Phenols; D016547:Kinesins; D017239:Paclitaxel